Skin Cancer & Melanoma

Binimetinib tablets at 45 mg received tentative FDA approval for patients with melanoma and NSCLC.

A panel of exerts discussed key takeaways happening in the field of cutaneous squamous cell carcinoma.

Sarah Weiss, MD, highlights pivotal updates in uveal melanoma, intratumoral neoadjuvant therapy, and Merkel cell carcinoma from the 2026 ASCO Annual Meeting.

Catch up on major clinical trials reshaping treatment for brain metastases, Merkel cell carcinoma, cervical cancer, and head and neck cancer, all from ASCO 2026.

Findings from the OptimUM-02 trial may support a new potential therapeutic standard for patients with HLA-A*02:01–negative metastatic uveal melanoma.

Neoadjuvant ipilimumab plus nivolumab and relatlimab achieved a major pathologic response in 73.7% of patients with resectable stage III/IV melanoma.

Data from the KEYNOTE-942 trial confirmed a durable benefit with intismeran plus pembrolizumab among patients with high-risk melanoma.

In 897 patients with advanced melanoma treated with ICI, conditional 5-year PFS rose from 29% at baseline to 91% for those progression-free at 4 years.

An OS of 32.9 months was noted with RP1 plus nivolumab for patients who had progressed on prior anti-PD-1 therapy with advanced melanoma.

Statistical significance was not met with either dose level of fianlimab plus cemiplimab compared with the control arm for patients with advanced melanoma.

iSCIB1+ continues to be studied in the SCOPE trial for patients with advanced melanoma.

Key data from the ATLAS-IT-05 study showed the activity of the oncolytic peptide ruxotemitide plus pembrolizumab in refractory metastatic melanoma.

The 5-year OS rate was 16% and 8% in the tebentafusp and control arms, respectively, for patients with HLA-A*02:01–positive uveal melanoma.

PFS showed statistically significant improvement with darovasertib plus crizotinib in the first line for patients with HLA-A*A2:01–negative metastatic uveal melanoma.

The FDA cited that the data provided for RP1 were insufficient and did not provide substantial evidence of effectiveness for this population.

The SkinJect data set found an overall response rate of approximately 80% for patients with nodular basal cell carcinoma receiving 200 µg of doxorubicin microneedle array.

DecisionDx-Melanoma’s i31-SLNB accurately predicted low nodal positivity and high recurrence-free survival in patients with cutaneous melanoma.

SkinCure Oncology filed a federal lawsuit against CMS and HHS to challenge the elimination of reimbursement for image-guided radiation therapy for nonmelanoma skin cancer.

A clinical clearance rate of 73% was noted among patients with basal cell carcinoma receiving 200 ug of doxorubicin microneedle array.

Explore the latest clinical data and therapeutic strategies for acral, mucosal, and uveal melanomas from Mark B. Faries, MD, FACS.

James Larkin, MD, PhD, highlighted toxicities associated with immune checkpoint inhibitors in melanoma at a recent Physicians Education Resource meeting.

Omid Hamid, MD, presented at the 22nd Annual International Symposium on Melanoma and Other Cutaneous Malignancies on the evolving landscape of perioperative immunotherapy and targeted therapy.

Researchers analyzed postoperative complications and survival outcomes in patients with melanoma who underwent therapeutic lymph node dissection.

Aminolevulinic acid plus red lamp therapy was given an sNDA by the FDA for the treatment of superficial basal cell carcinoma.

Nivolumab improved 9-year recurrence-free survival compared with ipilimumab for resected stage III or IV melanoma in the phase 3 CheckMate 238 trial.